What is Lifesci Capital’s Forecast for TARS FY2025 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a report released on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville anticipates that the company will post earnings per share of ($1.65) for the year. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q4 2025 earnings at ($0.11) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million.

Other research analysts also recently issued research reports about the company. Guggenheim restated a “buy” rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Barclays dropped their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday. Finally, Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $61.33.

Tarsus Pharmaceuticals Stock Up 2.1 %

Shares of NASDAQ TARS opened at $44.48 on Thursday. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The business has a 50-day simple moving average of $50.97 and a two-hundred day simple moving average of $43.13. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.70 billion, a P/E ratio of -11.67 and a beta of 1.01.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of TARS. Crowley Wealth Management Inc. bought a new stake in Tarsus Pharmaceuticals in the 4th quarter worth approximately $25,000. GF Fund Management CO. LTD. bought a new stake in Tarsus Pharmaceuticals in the 4th quarter worth approximately $44,000. R Squared Ltd bought a new stake in Tarsus Pharmaceuticals in the 4th quarter worth approximately $53,000. FMR LLC lifted its position in Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after buying an additional 3,537 shares during the last quarter. Finally, Quarry LP bought a new stake in Tarsus Pharmaceuticals in the 4th quarter worth approximately $166,000. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.